Renal Function in Patients Receiving Tenofovir With Ritonavir/Lopinavir or Ritonavir/Atazanavir in the HIV Outpatient Study (HOPS) Cohort
- 15 December 2006
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 43 (5) , 626-628
- https://doi.org/10.1097/01.qai.0000242461.35768.45
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVNew England Journal of Medicine, 2006
- Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapyHIV Medicine, 2006
- Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug InteractionsClinical Infectious Diseases, 2006
- Changes in Renal Function Associated with Tenofovir Disoproxil Fumarate Treatment, Compared with Nucleoside Reverse‐Transcriptase Inhibitor TreatmentClinical Infectious Diseases, 2005
- Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre studyNephrology Dialysis Transplantation, 2005
- Renal safety of tenofovir in HIV treatment-experienced patientsAIDS, 2004
- Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 InfectionAnnals of Internal Medicine, 2003
- Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studyAIDS, 2002
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976